400,000 Shares in Oric Pharmaceuticals, Inc. $ORIC Bought by Blue Owl Capital Holdings LP

Blue Owl Capital Holdings LP acquired a new stake in shares of Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 400,000 shares of the company’s stock, valued at approximately $4,332,000. Oric Pharmaceuticals comprises 0.7% of Blue Owl Capital Holdings LP’s portfolio, making the stock its 25th biggest holding.

Other institutional investors also recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Oric Pharmaceuticals by 26.0% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,732 shares of the company’s stock valued at $39,000 after purchasing an additional 977 shares during the period. California State Teachers Retirement System boosted its holdings in shares of Oric Pharmaceuticals by 3.9% in the fourth quarter. California State Teachers Retirement System now owns 33,959 shares of the company’s stock worth $278,000 after buying an additional 1,270 shares during the last quarter. The Manufacturers Life Insurance Company boosted its holdings in shares of Oric Pharmaceuticals by 1.6% in the fourth quarter. The Manufacturers Life Insurance Company now owns 128,649 shares of the company’s stock worth $1,042,000 after buying an additional 1,985 shares during the last quarter. Federation des caisses Desjardins du Quebec grew its position in Oric Pharmaceuticals by 100.0% during the fourth quarter. Federation des caisses Desjardins du Quebec now owns 4,000 shares of the company’s stock valued at $33,000 after buying an additional 2,000 shares during the period. Finally, Arizona State Retirement System grew its position in Oric Pharmaceuticals by 21.0% during the fourth quarter. Arizona State Retirement System now owns 12,163 shares of the company’s stock valued at $99,000 after buying an additional 2,107 shares during the period. Institutional investors own 95.05% of the company’s stock.

Analyst Upgrades and Downgrades

ORIC has been the subject of a number of research reports. Wall Street Zen raised shares of Oric Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Saturday, July 25th. Citigroup cut their price objective on shares of Oric Pharmaceuticals from $17.00 to $16.00 and set a “buy” rating for the company in a research report on Tuesday, May 5th. The Goldman Sachs Group upgraded Oric Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $15.00 price objective for the company in a research note on Friday, May 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oric Pharmaceuticals in a report on Friday, July 17th. Finally, HC Wainwright lifted their target price on Oric Pharmaceuticals from $25.00 to $27.00 and gave the company a “buy” rating in a research report on Monday, August 10th. Thirteen equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $19.45.

Oric Pharmaceuticals Trading Down 5.3%

NASDAQ ORIC opened at $13.88 on Friday. Oric Pharmaceuticals, Inc. has a 12 month low of $7.23 and a 12 month high of $14.93. The stock has a market cap of $1.44 billion, a price-to-earnings ratio of -10.28 and a beta of 1.02. The company’s 50 day moving average is $11.22 and its two-hundred day moving average is $10.60.

Oric Pharmaceuticals (NASDAQ:ORIC) last posted its quarterly earnings results on Monday, August 3rd. The company reported ($0.38) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.02). Sell-side analysts forecast that Oric Pharmaceuticals, Inc. will post -1.53 EPS for the current year.

Oric Pharmaceuticals Company Profile

Oric Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The firm is dedicated to discovering and developing small molecule therapeutics designed to overcome resistance mechanisms in solid tumor oncology. Its research efforts focus on identifying novel targets and advancing precision medicines that can restore or enhance patient response when standard therapies fail.

The company’s pipeline features lead candidates such as ORIC-101, a selective, orally available antagonist of the glucocorticoid receptor currently being evaluated in Phase 1/2 trials for patients with solid tumors who have acquired resistance to chemotherapy and hormonal agents.